NASDAQ : IART

Integra LifeSciences Holdings Corporation

$17.25 USD

$0.15 (0.88%)

Volume
623.76K
Average Volume
1.02M
Market Capitalization
$1.34B
P/E Ratio
-187.09
Dividend Yield
0.00%
Price Target
$19.00
Year High
$20.49
Year Low
$8.70
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.40
Company Overview

NASDAQ

Stuart Essig

Medical - Devices

Healthcare

IART

4427

US

USD

https://www.integralife.com

609 275 0500

457985208

0000917520

Liquidity Metrics

1.94

3.40

1.98

0.62

0.00

Sales & Valuation

$1.64B

0.81

1.28

34.62

0.50

Profitability

-$6.73

-$516.47M

-0.44%

-0.01%

-0.69%

-0.20%

P/E Metrics

-187.09

-1.87

-1.87

Analyst Price Target & Rating

$19.00

$25.00

$19.00

Sell

2/5

26 Analysts

-9.21%

Financial Health Scores

1.31

5/9

$833.5M

$3.59B

$2.54B

$96.06M

Key Metrics (TTM)

$3.17B

1.92

15.03

3.40

-0.69%

19.92%

-0.54%

2.89%

253 days

Company Executives
Name Title
Christopher Ward Senior Director of Investor Relations
Stuart Essig CEO, President & Chairman
Teshtar Elavia Corporate VP & Chief Technology Officer
Raymond D. Turner FAANS Corporate Vice President & Chief Medical Officer
Harvinder Singh Executive Vice President & President of International Business
Jeffrey Mosebrook Senior Vice President of Finance & Principal Accounting Officer
Michael J. McBreen Executive VP & Chief Commercial Officer
Robert T. Davis Jr. Executive Vice President of Tissue Reconstruction and Distributed Technologies
Michael D. Hutchinson Executive Vice President, Chief Legal Officer & Secretary
Laurene Isip Vice President of Global Corporate Communications & Public Relations
Chantal Veillon-Berteloot Executive Vice President & Chief Human Resources Officer
Lea Daniels Knight Executive Vice President & Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Integra LifeSciences Holdings Corporation (NASDAQ:IART) Stock

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, variou ... s instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock

2026-08-05 10:51:07

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript

2026-07-29 19:33:26

Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript

3 Stocks Showing Breakout Potential Ahead of August

2026-07-29 16:01:05

Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.

Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

2026-07-29 11:31:10

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Integra LifeSciences Q2 Earnings Call Highlights

2026-07-29 11:07:44

Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.

Integra LifeSciences (IART) Q2 Earnings Top Estimates

2026-07-29 08:31:22

Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.

Integra LifeSciences Reports Second Quarter 2026 Financial Results

2026-07-29 06:00:00

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.

Here's Why Integra LifeSciences (IART) is a Strong Value Stock

2026-07-28 10:41:18

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Frequently Asked Questions

What is the current Integra LifeSciences Holdings Corporation (IART) stock price?

Integra LifeSciences Holdings Corporation(NASDAQ:IART) stock price is $17.25 in the last trading session. During the trading session, IART stock reached the peak price of $20.49 while $8.7 was the lowest point it dropped to. The percentage change in IART stock occurred in the recent session was 0.88% while the dollar amount for the price change in IART stock was $0.15.

IART's industry and sector of operation?

The NASDAQ listed IART is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of IART?

Christopher Ward | Senior Director of Investor Relations
Stuart Essig | CEO, President & Chairman
Teshtar Elavia | Corporate VP & Chief Technology Officer
Raymond D. Turner FAANS | Corporate Vice President & Chief Medical Officer
Harvinder Singh | Executive Vice President & President of International Business

How many employees does IART have?

Number of IART employees currently stands at 4427. IART operates from 1100 Campus Road, Princeton, NJ 08540, US.

Link for IART official website?

Official Website of IART is: https://www.integralife.com

How do I contact IART?

IART could be contacted at phone #609 275 0500 and can also be accessed through its website. IART operates from 1100 Campus Road, Princeton, NJ 08540, US.

How many shares of IART are traded daily?

The average number of IART shares traded daily for last 3 months was 1.02M.

What is the market cap of IART currently?

The market value of IART currently stands at $1.34B with its latest stock price at $17.25